Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma

Clinical Cancer Research

Volumn 13, Issue 16, 2007, Pages 4740-4749

  Gumz, Michelle L ^a,f   Zou, Hongzhi ^b   Kreinest, Pamela A ^a   Childs, April C ^a   Belmonte, Leandra S ^a   LeGrand, Shauna N ^a   Wu, Kevin J ^a   Luxon, Bruce A ^c   Sinha, Mala ^c   Parker, Alexander S ^a   Sun, L Z ^d   Ahlquist, David A ^b   Wood, Christopher G ^e   Copland, John A ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC ROCHESTER   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^d Mays Cancer Center at UT Health San Antonio   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FRIZZLED RELATED PROTEIN; GLYCOPROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CULTURE; CLEAR CELL CARCINOMA; CONTROLLED STUDY; FEMALE; GENOMICS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; METHYLATION; MOUSE; NONHUMAN; NUDE MOUSE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION;

ANIMALS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; DNA METHYLATION; FEMALE; GLYCOPROTEINS; HUMANS; KIDNEY NEOPLASMS; MICE; PHENOTYPE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS; WNT PROTEINS;

EID: 34548071005     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0143     Document Type: Article

References (52)

1. Chow WH, Devesa SS, Warren JL, Fraumeni JF, Jr. Rising incidence of renal cell cancer in the United States. JAMA 1999;281:1628-31.
2. Moore LE, Wilson RT, Campleman SL. Lifestyle factors, exposures, genetic susceptibility, and renal cell cancer risk: a review. Cancer Invest 2005;23:240-55.
3. Maynard MA, Ohh M. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer. Am J Nephrol 2004;24:1-13.
4. Ollerenshaw M, Page T, Hammonds J, Demaine A. Polymorphisms in the hypoxia inducible factor-1α gene (HIF1A) are associated with the renal cell carcinoma phenotype. Cancer Genet Cytogenet 2004;153:122-6.
5. Weber KL, Doucet M, Price JE, Baker C, Kim SJ, Fidler IJ. Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice. Cancer Res 2003;63:2940-7.
6. Jacobsohn KM, Wood CG. Adjuvant therapy for renal cell carcinoma. Semin Oncol 2006;33:576-82.
7. Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 2003;1653:1-24.
8. Vincan E. Frizzled/WNT signalling: the insidious promoter of tumour growth and progression. Front Biosci 2004;9:1023-34.
9. Widelitz R. Wnt signaling through canonical and noncanonical pathways: recent progress. Growth Factors 2005;23:111-6.
10. Suzuki H, Ueda T, Komiya A, et al. Mutational state of von Hippel-Lindau and adenomatous polyposis coli genes in renal tumors. Oncology 1997;54:252-7.
11. Kim YS, Kang YK, Kim JB, Han SA, Kim KI, Paik SR. β-Catenin expression and mutational analysis in renal cell carcinomas. Pathol Int 2000;50:725-30.
12. Bilim V, Kawasaki T, Katagiri A, Wakatsuki S, Takahashi K, Tomita Y. Altered expression of β-catenin in renal cell cancer and transitional cell cancer with the absence of β-catenin gene mutations. Clin Cancer Res 2000;6:460-6.
13. Shiina H, Igawa M, Breault J, et al. The human T-cell factor-4 gene splicing isoforms, Wnt signal pathway, and apoptosis in renal cell carcinoma. Clin Cancer Res 2003;9:2121-32.
14. Zang T, Zhuang L, Zhang Z, Xin D, Guo Y. Expression of β-catenin in renal cell carcinoma. Chin Med J Engl 2001;114:152-4.
15. Janssens N, Andries L, Janicot M, Perera T, Bakker A. Alteration of frizzled expression in renal cell carcinoma. Tumour Biol 2004;25:161-71.
16. Kawano Y, Kypta R. Secreted antagonists of the Wnt signalling pathway. J Cell Sci 2003;116:2627-34.
17. Rubin JS, Barshishat-Kupper M, Feroze-Merzoug F, Xi ZF. Secreted WNT antagonists as tumor suppressors: pro and con. Front Biosci 2006;11:2093-105.
18. Caldwell GM, Jones C, Gensberg K, et al. The Wnt antagonist sFRP1 in colorectal tumorigenesis. Cancer Res 2004;64:883-8.
19. Fukui T, Kondo M, Ito G, et al. Transcriptional silencing of secreted frizzled related protein 1 (SFRP1) by promoter hypermethylation in non-small-cell lung cancer. Oncogene 2005;24:6323-7.
20. Takada T, Yagi Y, Maekita T, et al. Methylation-associated silencing of the Wnt antagonist SFRP1 gene in human ovarian cancers. Cancer Sci 2004;95:741-4.
21. Veeck J, Niederacher D, An H, et al. Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis. Oncogene 2006;25:3479-88.
22. Urakami S, Shiina H, Enokida H, et al. Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA. Clin Cancer Res 2006;12:6989-97.
23. Dahl E, Wiesmann F, Woenckhaus M, et al. Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma. Oncogene online publication March 12, 2007.
24. Fukuhara K, Kariya M, Kita M, et al. Secreted frizzled related protein 1 is overexpressed in uterine leiomyomas, associated with a high estrogenic environment, and unrelated to proliferative activity. J Clin Endocrinol Metab 2002;87:1729-36.
25. Joesting MS, Perrin S, Elenbaas B, et al. Identification of SFRP1 as a candidate mediator of stromal-to-epithelial signaling in prostate cancer. Cancer Res 2005;65:10423-30.
26. Suzuki H, Watkins DN, Jair KW, et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 2004;36:417-22.
27. Copland JA, Davies PJ, Shipley GL, Wood CG, Luxon BA, Urban RJ. The use of DNA microarrays to assess clinical samples: the transition from bedside to bench to bedside. Recent Prog Horm Res 2003;58:25-53.
28. Zou H, Molina JR, Harrington JJ, et al. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus. Int J Cancer 2005;116:584-91.
29. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔC(T)) method. Methods 2001;25:402-8.
30. Grossman HB, Wedemeyer G, Ren LQ. Human renal carcinoma: characterization of five new cell lines. J Surg Oncol 1985;28:237-44.
31. Copland JA, Luxon BA, Ajani L, et al. Genomic profiling identifies alterations in TGFβ signaling through loss of TGFβ receptor expression in human renal cell carcinogenesis and progression. Oncogene 2003;22:8053-62.
32. Vogt PK. Jun, the oncoprotein. Oncogene 2001;20:2365-77.
33. Iavarone C, Catania A, Marinissen MJ, et al. The platelet-derived growth factor controls c-myc expression through a JNK- and AP-1-dependent signaling pathway. J Biol Chem 2003;278:50024-30.
34. Kaspar M, Zardi L, Neri D. Fibronectin as target for tumor therapy. Int J Cancer 2006;118:1331-9.
35. Carducci MA, Jimeno A. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin Cancer Res 2006;12:6296-300s.
36. Musgrove EA. Cyclins: roles in mitogenic signaling and oncogenic transformation. Growth Factors 2006;24:13-9.
37. Karim R, Tse G, Putti T, Scolyer R, Lee S. The significance of the Wnt pathway in the pathology of human cancers. Pathology 2004;36:120-8.
38. Clevers H. Wnt/β-catenin signaling in development and disease. Cell 2006;127:469-80.
39. Pages G, Pouyssegur J. Transcriptional regulation of the vascular endothelial growth factor gene - a concert of activating factors. Cardiovasc Res 2005;65:564-73.
40. Kurose K, Sakaguchi M, Nasu Y, et al. Decreased expression of REIC/Dkk-3 in human renal clear cell carcinoma. J Urol 2004;171:1314-8.
41. Steelman CA, Recknor JC, Nettleton D, Reecy JM. Transcriptional profiling of myostatin-knockout mice implicates Wnt signaling in postnatal skeletal muscle growth and hypertrophy. FASEB J 2006;20:580-2.
42. Lodygin D, Epanchintsev A, Menssen A, Diebold J, Hermeking H. Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res 2005;65:4218-27.
43. Stoehr R, Wissmann C, Suzuki H, et al. Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. Lab Invest 2004;84:465-78.
44. Kim WY, Kaelin WG, Jr. Molecular pathways in renal cell carcinoma-rationale for targeted treatment. Semin Oncol 2006;33:588-95.
45. Reu FJ, Leaman DW, Maitra RR, et al. Expression of RASSF1A, an epigenetically silenced tumor suppressor, overcomes resistance to apoptosis induction by interferons. Cancer Res 2006;66:2785-93.
46. Calviello G, Resci F, Serini S, et al. Docosahexaenoic acid induces proteasome-dependent degradation of β-catenin, down-regulation of survivin, and apoptosis in human colorectal cancer cells not expressing COX-2. Carcinogenesis 2007;28:1202-9.
47. Singh S, Khar A. Biological effects of curcumin and its role in cancer chemoprevention and therapy. Anticancer Agents Med Chem 2006;6:259-70.
48. Woo JH, Kim YH, Choi YJ, et al. Molecular mechanisms of curcumin-induced cytotoxicity: induction of apoptosis through generation of reactive oxygen species, down-regulation of Bcl-XL and IAP, the release of cytochrome c, and inhibition of Akt. Carcinogenesis 2003;24:1199-208.
49. Miller WH, Jr., Reyno LM, Loewen GR, et al. A phase I-II study of 9-cis retinoic acid and interferon-α2b in patients with advanced renal-cell carcinoma: an NCIC Clinical Trials Group study. Ann Oncol 2000;11:1387-9.
50. Motzer RJ, Schwartz L, Law TM, et al. Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro. J Clin Oncol 1995;13:1950-7.
51. Liu TH, Raval A, Chen SS, Matkovic JJ, Byrd JC, Plass C. CpG island methylation and expression of the secreted frizzled-related protein gene family in chronic lymphocytic leukemia. Cancer Res 2006;66:653-8.
52. He B, Reguart N, You L, et al. Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations. Oncogene 2005;24:3054-8.